Recent Data on the Treatment of Pulmonary Arterial Hypertension: An Expert Interview With Dr. Steven Nathan
The last decade has witnessed remarkable improvements in the understanding and treatment of pulmonary arterial hypertension (PAH). Data were presented at American College of Chest Physicians (ACCP) meeting on several studies focusing on new approaches to treating PAH. Editorial Director Nancy Otto, PharmD, had the opportunity to discuss new data on PAH with Steven Nathan, MD, Medical Director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia. Dr. Nathan is a member of the Medscape Pulmonary Medicine Advisory Board. Medscape: Hello. I'd like to welcome Dr. Steven Nathan, Medical Director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia. Dr. Nathan also serves as a member of the Medscape Pulmonary Medicine Advisory Board. We're discussing data on pulmonary arterial hypertension (PAH) from the CHEST 2008 conference in Philadelphia. Welcome, Dr. Nathan. Dr. Nathan: Thank you very much, Nancy. Thanks for inviting me to talk to you on this subject. Medscape: Data from several PAH trials were presented at CHEST 2008, and several of the discussions focused on combination therapy and monotherapy. Would you please discuss highlights of some of these studies?